Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Clinical trial NCT04522167 · COMPLETED
Trial details
- NCT number
- NCT04522167
- Sponsor
- Bioeq GmbH
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-21
- Primary completion
- 2022-06-23
- Enrollment
- 434
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.